Our lead product candidates, Asentar™ (DN-101) and AQ4N (Banoxantrone), are concrete examples of our conviction that We Can™ successfully identify, license, and develop novel therapeutics that may improve clinical outcomes for patients with cancer, with a goal of obtaining regulatory approval from the United States Food and Drug Administration. Our strategies include efforts to develop anti-cancer agents that may reduce the toxicities associated with current therapies. We are also attempting to mitigate development risks by licensing product candidates with well-characterized mechanisms of action and supportive pre-clinical or clinical data. In addition, our oncology development expertise enables us to design efficient clinical and commercialization programs geared towards providing cancer patients with treatment options that offer improvements over current standards of care.
Click on the links below to learn more about our oncology focus, our pipeline, and our lead products, Asentar and AQ4N.
Oncology Focus
Development Pipeline
About Asentar
About AQ4N
Posters & Abstracts
|
|
 |
|
